We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Therapix Biosciences Ltd | NASDAQ:TRPX | NASDAQ | Depository Receipt |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.317 | 0.3101 | 0.315 | 0 | 01:00:00 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of: December 2017 (Report No. 1)
Commission file number: 001- 38041
THERAPIX BIOSCIENCES LTD.
(Translation of registrant’s name into English)
4 Ariel Sharon Street
HaShahar Tower, 16th Floor
Givatayim 5320047, Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1): ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7): ¨
Resignation of Chief Financial Officer and Entry into Separation Agreement
Therapix Biosciences Ltd. (the “Company”) and Josh Blacher, the Company’s Chief Financial Officer entered into a mutually-amicable separation agreement (the “Separation Agreement”) on December 19, 2017 (the “Effective Date”). Mr. Blacher has served as the Company’s Chief Financial Officer since May 2017. The Company is in the process of searching for a new Chief Financial Officer and Mr. Blacher will support an orderly transition of his overall responsibilities to his replacement. Under the terms of the Separation Agreement, Mr. Blacher will receive severance in the amount of (i) three months’ salary through the end of the notice period following the Effective Date and (ii) a bonus equal to two months of salary. In addition, all of Mr. Blacher’s outstanding options to purchase 47,500 American Depositary Shares of the Company will be deemed fully vested as of the Effective Date and may be exercised within a period of 90 days (or by June 19, 2018).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Therapix Biosciences Ltd. | |||
(Registrant) | |||
By: | /s/ Ascher Shmulewitz | ||
Name: | Ascher Shmulewitz, M.D, Ph.D. | ||
Title: | Chief Executive Officer |
Date: December 26, 2017
1 Year Therapix Biosciences Chart |
1 Month Therapix Biosciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions